<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005794</url>
  </required_header>
  <id_info>
    <org_study_id>1999-355</org_study_id>
    <secondary_id>P30CA014520</secondary_id>
    <secondary_id>WCCC-CO-99906</secondary_id>
    <secondary_id>ASTA-D-21266</secondary_id>
    <secondary_id>NCI-T99-0036</secondary_id>
    <secondary_id>CDR0000067752</secondary_id>
    <nct_id>NCT00005794</nct_id>
  </id_info>
  <brief_title>Perifosine in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Trial of Perifosine on a Loading Dose/Maintenance Dose Schedule in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <brief_summary>
    <textblock>
      RATIONALE: Perifosine may stop the growth of tumor cells by stopping blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of perifosine in treating patients who have&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of perifosine on a loading dose/maintenance&#xD;
           dose schedule in patients with advanced solid tumors.&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Investigate the relationship between pharmacokinetic parameters and toxicity of this&#xD;
           drug in these patients.&#xD;
&#xD;
        -  Determine the recommended starting dose for phase II trials on this drug schedule in&#xD;
           these patients.&#xD;
&#xD;
        -  Evaluate the pharmacodynamic parameters on peripheral blood lymphocytes both before and&#xD;
           during drug administration in these patients.&#xD;
&#xD;
        -  Determine any changes in the MTD with prolonged administration (3 months, 6 months) of&#xD;
           this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive a loading dose of oral perifosine 4 times a day for 4-8 doses followed by a&#xD;
      daily maintenance dose. Treatment continues every 28 days in the absence of unacceptable&#xD;
      toxicity or disease progression.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating loading doses and maintenance doses of perifosine&#xD;
      until the maximum tolerated dose (MTD) of each is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 6 patients experience dose-limiting toxic effects.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 20-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perifosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed locally unresectable or metastatic malignancy that is&#xD;
             considered incurable&#xD;
&#xD;
          -  Refractory to further treatment with known forms of effective therapy&#xD;
&#xD;
          -  No clinically active CNS metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 6 months&#xD;
             after study participation&#xD;
&#xD;
          -  Maintaining a reasonable state of nutrition consistent with weight maintenance&#xD;
&#xD;
               -  No recent history of weight loss greater than 10% of current body weight&#xD;
&#xD;
          -  No frequent vomiting/poor alimentation&#xD;
&#xD;
          -  No other serious concurrent medical illness that would preclude study therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin and nitrosoureas) and&#xD;
             recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
               -  Patients who have progressive disease while being treated with LHRH agonists,&#xD;
                  antiestrogens, or antitestosterones for at least 3 months may remain on these&#xD;
                  agents if in their best interest&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 21 days since prior major surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn Van Ummersen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>October 7, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2003</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

